What happens to cartilage inside the jaw joint

Persistent jaw pain, clicking on opening, or episodes where the joint seems to catch or lock — these are the symptoms that bring patients to a specialist after months of management that has not moved the needle. In most cases, the underlying problem is structural: cartilage damage within the temporomandibular joint (TMJ) that standard conservative care cannot reverse.

The TMJ is anatomically unusual. It contains two distinct cartilage tissues: a fibrocartilage disc that sits between the temporal bone and the mandibular condyle, acting as a shock absorber and allowing the joint's hinge-and-glide movement; and a hyaline-like fibrocartilage layer covering the condylar surface itself. Damage to either structure — through grinding, loading, inflammatory arthritis, or wear — produces the familiar pattern of pain, restricted movement, and joint noise that characterises temporomandibular dysfunction (TMD).

Cartilage in any joint has limited capacity for self-repair, because it is avascular: it receives no direct blood supply and therefore lacks the ready delivery of progenitor cells that allows bone or soft tissue to heal spontaneously. Once focal defects develop on the condylar surface or the disc, they tend to persist or progress.

Splints, physiotherapy, and anti-inflammatory injections — including corticosteroid and hyaluronic acid — can reduce pain and protect function, but they do not address the cartilage defect itself. Surgical access to the TMJ, meanwhile, carries meaningful complexity given its proximity to the facial nerve and its anatomical depth, which makes minimally invasive approaches particularly relevant for patients who have exhausted first-line options.

How ChondroFiller works as an injectable scaffold

ChondroFiller® (marketed as Liquid Cartilage™, manufactured by Meidrix Biomedicals GmbH) is a CE-marked Class III medical device — a category reserved for implants that interact directly with biological processes rather than simply occupying space. Its active ingredient is an acellular, murine-derived Type I collagen solution: there are no donor cells in the syringe.

The therapeutic process is described as acellular matrix-induced chondrogenesis, which in practical terms means the injected material creates the conditions for the patient's own body to rebuild cartilage. The sequence runs as follows. Once placed into the defect under ultrasound guidance — in a fluid joint environment, without any requirement to dry or surgically prepare the joint — the collagen solution self-gels within minutes, conforming to the shape of the damaged area and forming a stable scaffold. That scaffold is chemotactic: it releases signals that draw progenitor cells from the surrounding synovium and subchondral tissue into the defect space. Those recruited cells differentiate into chondrocytes and begin depositing new extracellular matrix. Over approximately six to twelve months the original collagen scaffold gradually degrades and is replaced by the patient's own repair tissue.

This sequence sets ChondroFiller apart from the two injection categories patients most commonly encounter. Hyaluronic acid is a viscosupplement — it lubricates and may buffer load, but it does not rebuild cartilage structure. Permanent hydrogel fillers such as polyacrylamide occupy space within the joint and remain there indefinitely. ChondroFiller is neither: it is a temporary scaffold that promotes endogenous repair and is designed to be replaced by the tissue it helps generate.

The biological case for using ChondroFiller in the TMJ

The first question before applying any progenitor-recruiting scaffold to a new joint is whether the local cell population can respond to it. For the TMJ, the preclinical answer is encouraging. Research on mandibular condyle cells has found that superficial fibroblastic layer cells (SLCs) — the most accessible progenitor pool in that tissue — show chondrogenic potential comparable to the deeper cartilage layer cells (CLCs) typically targeted in scaffold-based repair. The scaffold's chemotactic principle does not require a specialised cell type: it needs a population capable of chondrogenic differentiation, and the TMJ condyle contains one.

In vivo evidence adds weight. A preclinical study using a bilayered scaffold implanted into goat TMJ condyle defects demonstrated full neo-cartilage coverage within two months, producing ordered fibrocartilage and hyaline-like cartilage matching the native condylar architecture. That work involved a PLGA-g-PCL construct rather than ChondroFiller itself, but the relevance holds: TMJ fibrocartilage can be reconstituted through scaffold-mediated cell recruitment in an appropriate biological environment.

ChondroFiller's mechanism does not require joint-specific reformulation — the same chemotactic principle operates wherever the scaffold is placed. The TMJ's biological complexity lies one step downstream. The joint contains two structurally distinct cartilage territories: a fibrocartilage disc and a hyaline-like condylar surface. Their architectural heterogeneity is acknowledged in the tissue-engineering literature as a challenge not consistently present in other joints. That complexity is distinct from the question of whether progenitor cells will migrate into the scaffold — the preclinical cell data suggest they will — but it does mean the character and fidelity of any regenerated tissue in the TMJ remains an open biological question rather than a confirmed outcome.

No peer-reviewed clinical trial specifically evaluating ChondroFiller injection in the TMJ has been published to date. The application is best understood as a clinically logical extension of a well-evidenced platform: a recruitment mechanism demonstrated across multiple joints, applied to one whose cell biology supports it. The clinical outcomes discussed in the following section therefore draw on knee, hip, and ankle data — the settings where published trial results exist.

What the clinical evidence shows across joints

Across more than 19,000 procedures performed globally, ChondroFiller® has generated an outcomes dataset that now spans the knee, hip, ankle, and smaller joints — and the figures carry clinical weight rather than just statistical significance.

In the knee, IKDC scores improve by approximately 30 points on average, a gain that moves most patients across the threshold from significant functional limitation into the range where normal activity is restored. A peer-reviewed cohort study by Simeonov (2024, Journal of IMAB) followed 17 patients with a mean age of 31 through twelve months of follow-up, recording statistically significant improvements in both Lysholm and IKDC scores at three, six, and twelve months (p<0.05), with results holding stable between the six- and twelve-month assessments. Hip data show a Harris Hip Score improvement of approximately 33 points — a comparable magnitude of gain in a different scoring system, suggesting the effect is not anatomically confined to the knee.

Perhaps the most clinically meaningful figure for patients who worry that injections simply mask pain is the MOCART MRI score. Across published series, MOCART scores of 70–87 have been recorded: these are imaging assessments of cartilage fill and integration, not patient-reported symptom scales. A score in that range indicates structural repair tissue occupying the defect — evidence that the scaffold's recruitment mechanism is producing material change, not symptomatic cover.

Safety data are comparably favourable. The major complication rate sits at approximately 0%, with reoperation rates of 3–8% — substantially lower than the figures reported for autologous chondrocyte implantation (ACI/MACI, reoperation up to 37%) and microfracture (up to 41%).

These results derive from knee, hip, and ankle populations. TMJ-specific trial data have not yet been published, which is why the biological rationale outlined earlier matters as a bridging framework.

How the injection is carried out

Attending for a ChondroFiller® injection at the TMJ follows the same outpatient model used when the joint is injected with hyaluronic acid or corticosteroid — a route that clinicians have navigated under ultrasound guidance for years. No theatre admission, no general anaesthetic, and no surgical preparation of the joint space are required.

At the appointment, local anaesthesia is applied to the area. Ultrasound imaging is used throughout to guide placement, allowing the clinician to map the defect and confirm needle position in real time before the collagen solution is introduced. Because ChondroFiller self-gels within the fluid joint environment, there is no requirement to evacuate synovial fluid or dry the compartment beforehand — a step that arthroscopic surgical delivery does require. The scaffold forms in situ, layering over the worn surface from above; unlike surgical debridement, which works from the bone up, nothing is removed. For the TMJ, where arthroscopic access carries greater anatomical complexity than in the knee or hip, this intra-articular injection route removes a substantial barrier to treatment.

Patients typically report a sense of pressure during and briefly after placement. The clinician can observe the material settling into the defect on the ultrasound screen in real time, confirming accurate positioning. A short monitoring period follows before same-day discharge, with no wound or incision to manage on returning home.

Who may be suitable and what to expect in London

Patients most likely to be considered have focal cartilage defects in one or both TMJ condyles that have persisted through conservative management — physiotherapy, occlusal splinting, anti-inflammatory medication — without reaching end-stage pan-articular destruction where surgical reconstruction becomes the relevant conversation. The manufacturer's own documentation lists the jaw among the joints this scaffold is intended to address, alongside the knee, hip, shoulder, ankle, elbow, and wrist. Precise candidacy depends on defect geometry, surrounding fibrocartilage quality, and the balance of mechanical versus inflammatory pathology; imaging, typically MRI or cone-beam CT, is needed to characterise the defect before any treatment decision.

Recovery does not involve wound care or restricted jaw movement in the way surgical procedures do. The scaffold integrates and matures over the biological window described in the mechanism section above; at follow-up, MRI can confirm whether repair tissue has formed within the defect — a structural measure that goes beyond symptom scores alone.

In the UK, this is self-funded private treatment. At London Cartilage Clinic on Harley Street — the London access point for this pathway, where Professor Paul Y.F. Lee leads assessment and treatment — the guide cost for a single-box injection starts at approximately £3,000, inclusive of consultation, ultrasound guidance, the product, antibiotic cover, and a six-week review appointment; the treating clinician confirms the final figure at consultation, as larger or multi-site defects may require additional product.

For patients who think this pathway may be relevant to their TMJ condition, the most useful next step is a specialist assessment that reviews recent imaging, maps the defect, and sets any treatment decision against the full range of joint-preservation options available. An initial consultation can be arranged at londoncartilage.com.

1. [1] Temporomandibular joint dysfunction. https://en.wikipedia.org/?curid=30707 https://en.wikipedia.org/?curid=30707
2. [2] Temporomandibular joint. https://en.wikipedia.org/?curid=203139 https://en.wikipedia.org/?curid=203139
3. [3] Chondrogenic potential of superficial versus cartilage layer cells of the TMJ condyle in photopolymerizable gelatin-based hydrogels. (2024). https://doi.org/10.1177/09544119241267021 https://doi.org/10.1177/09544119241267021
4. [4] Implantation of ChondroFiller Liquid® as a Scaffold Material for the Treatment of Chondral Lesions of the Knee Joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] A Bilayered Scaffold with Segregated Hydrophilicity-Hydrophobicity Enables Reconstruction of Goat Hierarchical Temporomandibular Joint Condyle Cartilage. (2020). https://doi.org/10.1016/j.actbio.2020.11.031 https://doi.org/10.1016/j.actbio.2020.11.031
6. [6] Advances in 3D printing techniques for cartilage regeneration of temporomandibular joint disc and mandibular condyle. (2023). https://doi.org/10.18063/ijb.761 https://doi.org/10.18063/ijb.761